Skip to content
Peptigraph home

SLU-PP-332 and Retatrutide Together: What Is Known

SLU-PP-332 and Retatrutide taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
ERR agonist (not a peptide)Not FDA approved · research chemicalSLU-PP-332Experimental ERR agonist (not a peptide) with no human studies; in mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation, mimicking exercise.[6]GLP-1 & metabolicGLP-1 / GIP / glucagon triple agonistInvestigational · phase 3RetatrutideInvestigational triple GIP, GLP-1 and glucagon receptor agonist, not FDA-approved; a phase 3 TRIUMPH trial reported mean weight change of -25.0% at the 12-mg dose versus -3.9% with placebo.[1]GLP-1 & metabolic
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 0 results, 2 Oct 2026).

Neither is FDA approved for use in people, and we have no sourced data on combining them.
Each component

Side by side

Showing 10 of 12 fields where the two differ. Category, PCAC vote, Jul 2026 are the same or both unknown.

FieldSLU-PP-332Retatrutide
ClassERR agonist (not a peptide)GLP-1 / GIP / glucagon triple agonist
Also calledslupp, SLU-PPreta, GLP-3, LY3437943
FDA statusNot FDA approved · research chemicalInvestigational · phase 3
WADAWADA status unclearSLU-PP-332 is not named. S4.4 lists AMPK activators, PPAR-delta agonists and Rev-erb agonists; SLU-PP-332 is an ERR agonist, which the list does not mention. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance.Prohibited by WADA (S0)Retatrutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change.
Half-lifeNo published half-life foundPubMed search, 11 Oct 2026approximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040
Evidence strengthAnimal evidence, 2 of 4Strongest: The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806Human RCT evidence, 4 of 4Strongest: The New England journal of medicine 2026, PMID 42814954
Human studies we summarised0 human (0 randomized or controlled) of 7 summarised11 human (11 randomized or controlled) of 16 summarised
Typical study dosesNot reported in study abstractsPubMed search, 11 Oct 2026
Vial sizes sold5 mg5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026; 31 Mar 2026)

SLU-PP-332: mouse studies of an exercise mimetic

SLU-PP-332 increased oxidative muscle fibres and exercise endurance when given to mice.[14]

In pressure-overload heart failure in mice, SLU-PP-332 and a sister compound improved ejection fraction and survival.[15]

Retatrutide: human trial data

In a phase 2 type 2 diabetes substudy, total fat mass fell 26.1% in the pooled retatrutide 8 mg arms against 4.5% on placebo.[11]

In a phase 3 type 2 diabetes trial, the mean HbA1c change from baseline was -1.94% with retatrutide 12 mg against -0.81% with placebo.[16]

Retatrutide adverse events

In the large retatrutide obesity trial, gastrointestinal events were the most common adverse events.[1]

More SLU-PP-332 mouse data

In ageing mice, a pan-ERR agonist reversed kidney changes tied to mitochondrial dysfunction and inflammation.[17]

Together

The SLU-PP-332 with retatrutide search returned 0 PubMed records.

Calculated from pubmed query (retatrutide[tiab] OR LY3437943[tiab]) AND ("SLU-PP-332"[tiab]); search date 2026-10-02; records returned 0; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key retatrutide__slu-pp-332); no arithmetic applied.

Under WADA's S0 clause, drugs in clinical development without approval for human therapeutic use are prohibited at all times. Retatrutide is such a drug.[5]

Drugs@FDA returns no match for SLU-PP-332.[18]

Common questions

SLU-PP-332 vs retatrutide: which burns more fat?

Retatrutide has human fat-mass data, while SLU-PP-332 has only mouse and cell data on metabolism.[6]

Can you take SLU-PP-332 with retatrutide?

No study of the pair was found, and a recent review of pan-ERR agonists says clinical trials are needed.[19]

Sources

  1. 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  2. 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  3. 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
  4. 4Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
  5. 5World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  6. 6A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
  7. 7PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
  10. 10Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
  11. 11Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
  12. 12PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND ("SLU-PP-332"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13PubMed search: ("SLU-PP-332"[tiab] OR "SLU-PP-915"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  14. 14Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.ACS chemical biology · 2023PMID 36988910Accessed 2 Oct 2026
  15. 15Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.Circulation · 2024PMID 37961903Accessed 2 Oct 2026
  16. 16Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 42250575Accessed 2 Oct 2026
  17. 17Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.The American journal of pathology · 2023PMID 37717940Accessed 2 Oct 2026
  18. 18Drugs@FDA (openFDA) search: active ingredient "SLU-PP-332"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  19. 19[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications].Revista medica de Chile · 2026PMID 42024694Accessed 2 Oct 2026

Found an error? Report a correction.